Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Total Liabilities (2016 - 2026)

Iradimed has reported Total Liabilities over the past 14 years, most recently at $15.9 million for Q1 2026.

  • Quarterly Total Liabilities rose 35.97% to $15.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $15.9 million through Mar 2026, up 35.97% year-over-year, with the annual reading at $14.2 million for FY2025, 23.04% up from the prior year.
  • Total Liabilities was $15.9 million for Q1 2026 at Iradimed, up from $14.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $20.7 million in Q4 2023 and troughed at $9.8 million in Q3 2022.
  • The 5-year median for Total Liabilities is $11.8 million (2022), against an average of $12.5 million.
  • Year-over-year, Total Liabilities surged 75.12% in 2023 and then plummeted 44.51% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $11.8 million in 2022, then surged by 75.12% to $20.7 million in 2023, then plummeted by 44.51% to $11.5 million in 2024, then grew by 23.04% to $14.2 million in 2025, then increased by 12.13% to $15.9 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Total Liabilities are $15.9 million (Q1 2026), $14.2 million (Q4 2025), and $16.4 million (Q3 2025).